Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer

被引：55

作者：

Bouchahda, M. ^{[1
]}

Macarulla, T. ^{[2
]}

Spano, J. P. ^{[3
]}

Bachet, J. B. ^{[4
]}

Lledo, G. ^{[5
]}

Andre, T. ^{[6
]}

Landi, B. ^{[7
]}

Tabernero, J. ^{[2
]}

Karaboue, A.

Domont, J. ^{[3
]}

Levi, F.

Rougier, P. ^{[4
]}

机构：

[1] Hop Paul Brousse, Med Oncol Serv, F-94800 Villejuif, France

[2] Valle Hebron Univ Hosp, Barcelona, Spain

[3] Hop La Pitie Salpetriere, Paris, France

[4] Hop Ambroise Pare, Paris, France

[5] Clin St Jean, Lyon, France

[6] Hop Tenon, F-75970 Paris, France

[7] Hop Europeen Georges Pompidou, Paris, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 67卷 / 03期

关键词：

cetuximab; chemotherapy; colorectal cancer; elderly;

D O I：

10.1016/j.critrevonc.2008.02.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Few data are available from clinical trials for elderly patients receiving cetuximab. Patients and methods: The clinical data of consecutive patients aged >= 70 years given cetuximab for metastatic CRC were retrospectively captured from hospital pharmacy registries in seven centers. Results: Fifty-six patients received cetuximab with irinotecan. Median age was 76 years (70-84), 86% of patients were pretreated with fluoropyrimidines, irinotecan and oxaliplatin and 69.6% had documented resistance to irinotecan. Objective response rate was 21% (95% CI: 11-32%). The median progression-free survival was 4.4 months (95% Cl: 3.0-5.7 months) and the median overall survival was 16.0 months (95% CI: 13.5-18.5 months). Skin rash occurred in 75% of the patients (11% grade 3) and diarrhea in 80% (20% grades 3-4). Conclusion: Tolerability of cetuximab was acceptable in elderly patients with pretreated metastatic CRC. Efficacy appeared similar to that observed in younger patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：255 / 262

页数：8

共 50 条

[31] Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer [J].

Szemitko, Marcin ;

Golubinska-Szemitko, Elzbieta ;

Sienko, Jerzy ;

Falkowski, Aleksander ;

Wiernicki, Ireneusz .

CANCERS, 2023, 15 (02)

[32] Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis [J].

Parikh, Aparna R. ;

Gonzalez-Gugel, Elena ;

Smolyakova, Natalia ;

Jen, Min-Hua ;

Toms, Nikki ;

Lin, Yong ;

Kim, Jong Seok ;

Kopetz, Scott .

ONCOLOGIST, 2022, 27 (05) :371-379

[33] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer [J].

Ozaslan, Ersin ;

Topaloglu, Ulas Serkan ;

Inanc, Mevlude ;

Erdem, Umut Gokmen ;

Demir, Hacer ;

Arpaci, Erkan ;

Seker, Mehmet Metin ;

Karaaga, Mustafa ;

Kiziltepe, Melih ;

Eker, Baki ;

Ozkan, Metin .

JOURNAL OF BUON, 2017, 22 (04) :863-868

[34] Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study [J].

Sogabe, Susumu ;

Komatsu, Yoshito ;

Yuki, Satoshi ;

Kusumi, Takaya ;

Hatanaka, Kazuteru ;

Nakamura, Michio ;

Kato, Takashi ;

Miyagishima, Takuto ;

Hosokawa, Ayumu ;

Iwanaga, Ichiro ;

Sakata, Yuh ;

Asaka, Masahiro .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (04) :490-497

[35] Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study [J].

Feng, Qingyang ;

Wei, Ye ;

Ren, Li ;

Zheng, Peng ;

Yu, Yiyi ;

Ye, Qinghai ;

Ding, Jianyong ;

Chen, Jingwen ;

Chang, Wenju ;

Zhong, Yunshi ;

Zhu, Dexiang ;

Lin, Qi ;

Yang, Liangliang ;

Qin, Xinyu ;

Xu, Jianmin .

ONCOTARGET, 2016, 7 (10) :11380-11396

[36] Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study [J].

Tanioka, Hiroaki ;

Asano, Motoi ;

Yoshida, Ryousuke ;

Waki, Naohisa ;

Uno, Futoshi ;

Ishizaki, Masahiro ;

Yamashita, Kazuki ;

Morishita, Yuki ;

Nagasaka, Takeshi .

ONCOLOGY LETTERS, 2018, 16 (03) :3674-3680

[37] EFFICACY OF CETUXIMAB/PANITUMUMAB AFTER PREVIOUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER [J].

Gherman, Alexandra ;

Cainap, Calin ;

Vesa, Stefan-Cristian ;

Havasi, Andrei Dan ;

Trifon, Alexandra ;

Cainap, Simona Sorana ;

Crisan, Ovidiu ;

Irimie, Alexandru .

FARMACIA, 2020, 68 (04) :656-664

[38] Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases [J].

Alcaide, Julia ;

Delgado, Mayte ;

Legeren, Marta ;

Jurado, Jose Miguel ;

Blancas, Isabel ;

Pereda, Teresa ;

Lopez, Jorge ;

Garrido, Margarita ;

Sanchez, Maria J. ;

Garcia, Jose L. ;

Rueda, Antonio .

ONCOLOGY LETTERS, 2016, 12 (05) :3127-3134

[39] Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients [J].

Rachar, Veronika ;

Czejka, Martin ;

Kitzmueller, Marie ;

Buchner, Philipp ;

Lichtneckert, Maria ;

Greil, Richard ;

Geiler, Herbert ;

Dittrich, Christian .

ANTICANCER RESEARCH, 2016, 36 (09) :4715-4723

[40] Cetuximab for treatment of metastatic colorectal cancer [J].

Cerea, G. ;

Ricotta, R. ;

Schiavetto, I. ;

Maugeri, M. R. ;

Sartore-Bianchi, A. ;

Moroni, M. ;

Artale, S. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2006, 17 :VII66-VII67

← 1 2 3 4 5 →